<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To develop more effective chemotherapy regimens for childhood <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Between June 1991 and December 1996, we administered the <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analog 2-chlorodeoxyadenosine (2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>) to 73 children with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 20 children with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received one or two 5-day courses of 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> (8.9 mg/m(2)/d) given by continuous infusion </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients then received one to three courses of daunomycin, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and <z:chebi fb="0" ids="4911">etoposide</z:chebi> (DAV) remission induction therapy </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Seventy-two patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were assessable for response </plain></SENT>
<SENT sid="5" pm="."><plain>Their rate of complete remission (CR) was 24% after one course of 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>, 40% after two courses of 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>, and 78% after DAV therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 57 patients who entered CR, 11 subsequently underwent allogeneic bone marrow transplantation (BMT), and 40 underwent autologous BMT </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-nine patients remain in continuous CR after BMT </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients remain in CR after chemotherapy only </plain></SENT>
<SENT sid="9" pm="."><plain>The 5-year event-free survival (EFS) estimate was 40% (SE = 0.080%) </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with French-American-British (FAB) M5 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> had a higher rate of CR after treatment with 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> (45% after one course and 70.6% after two courses) than did others (P =.002) </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast, no patient with <z:e sem="disease" ids="C0023462" disease_type="Neoplastic Process" abbrv="">FAB M7</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 10) entered CR after treatment with 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Similarly, no patient with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 6) responded to 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Seven patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 14) had a partial response to one course of 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: This agent was well tolerated, and its toxicity was acceptable </plain></SENT>
<SENT sid="15" pm="."><plain>Future trials should examine the effectiveness of 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> given in combination with other agents effective against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>